How to buy ICON Public Limited Company stock - 02 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ICON Public Limited Company stock

Own ICON Public Limited Company stock in just a few minutes.

Fact checked

ICON Public Limited Company is a diagnostics & research business based in the US. ICON Public Limited Company shares (ICLR) are listed on the NASDAQ and all prices are listed in US Dollars. ICON Public Limited Company employs 15,250 staff and has a trailing 12-month revenue of around USD$2.8 billion.

How to buy shares in ICON Public Limited Company

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ICON Public Limited Company. Find the stock by name or ticker symbol: ICLR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ICON Public Limited Company reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ICON Public Limited Company, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ICON Public Limited Company. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ICON Public Limited Company share price

Use our graph to track the performance of ICLR stocks over time.

ICON Public Limited Company shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$104.275 - USD$223.62
50-day moving average USD$208.5542
200-day moving average USD$195.7678
Wall St. target priceUSD$206.43
PE ratio 34.6833
Dividend yield N/A (0%)
Earnings per share (TTM) USD$6.015

Buy ICON Public Limited Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ICON Public Limited Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is ICON Public Limited Company under- or over-valued?

Valuing ICON Public Limited Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICON Public Limited Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ICON Public Limited Company's P/E ratio

ICON Public Limited Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, ICON Public Limited Company shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ICON Public Limited Company's PEG ratio

ICON Public Limited Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2774. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICON Public Limited Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ICON Public Limited Company's EBITDA

ICON Public Limited Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$469.7 million.

The EBITDA is a measure of a ICON Public Limited Company's overall financial performance and is widely used to measure a its profitability.

ICON Public Limited Company financials

Revenue TTM USD$2.8 billion
Operating margin TTM 14.66%
Gross profit TTM USD$862.2 million
Return on assets TTM 8.71%
Return on equity TTM 20.42%
Profit margin 11.95%
Book value $32.423
Market capitalisation USD$11 billion

TTM: trailing 12 months

Shorting ICON Public Limited Company shares

There are currently 670,867 ICON Public Limited Company shares held short by investors – that's known as ICON Public Limited Company's "short interest". This figure is 26.9% down from 918,226 last month.

There are a few different ways that this level of interest in shorting ICON Public Limited Company shares can be evaluated.

ICON Public Limited Company's "short interest ratio" (SIR)

ICON Public Limited Company's "short interest ratio" (SIR) is the quantity of ICON Public Limited Company shares currently shorted divided by the average quantity of ICON Public Limited Company shares traded daily (recently around 203910.94224924). ICON Public Limited Company's SIR currently stands at 3.29. In other words for every 100,000 ICON Public Limited Company shares traded daily on the market, roughly 3290 shares are currently held short.

However ICON Public Limited Company's short interest can also be evaluated against the total number of ICON Public Limited Company shares, or, against the total number of tradable ICON Public Limited Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ICON Public Limited Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ICON Public Limited Company shares in existence, roughly 10 shares are currently held short) or 0.0129% of the tradable shares (for every 100,000 tradable ICON Public Limited Company shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ICON Public Limited Company.

Find out more about how you can short ICON Public Limited Company stock.

ICON Public Limited Company share dividends

We're not expecting ICON Public Limited Company to pay a dividend over the next 12 months.

Have ICON Public Limited Company's shares ever split?

ICON Public Limited Company's shares were split on a 2:1 basis on 13 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ICON Public Limited Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ICON Public Limited Company shares which in turn could have impacted ICON Public Limited Company's share price.

ICON Public Limited Company share price volatility

Over the last 12 months, ICON Public Limited Company's shares have ranged in value from as little as $104.275 up to $223.62. A popular way to gauge a stock's volatility is its "beta".

ICLR.US volatility(beta: 0.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICON Public Limited Company's is 0.8474. This would suggest that ICON Public Limited Company's shares are less volatile than average (for this exchange).

ICON Public Limited Company overview

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site